CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Authors
Borras F.E.
Buzas E.
+35 more
Camussi G.
Cappello F.
Carvalho J.
Cordeiro Da Silva A.
Del Portillo H.
El Andaloussi S.
Fais S.
Ficko Trček T.
Furlan R.
Giebel B.
Gursel I.
Hendrix A.
Kaeffer B.
Kosanovic M.
Kralj-Iglic V.
Lekka M.E.
Lipps G.
Llorente A.
Logozzi M.
Marcilla A.
Nazarenko I.
O'Driscoll L.
Oliveira C.
Pocsfalvi G.
Rajendran L.
Raposo G.
Rohde E.
Sammar M.
Siljander P.
Van Niel G.
Vasconcelos M.H.
Yliperttula M.L.
Yáñez-Mó M.
Zarovni N.
Zavec A.B.
Publication date
1 January 2016
Publisher
'American Chemical Society (ACS)'
Doi
Cite
Abstract
Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine. © 2016 American Chemical Society
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Bilkent University Institutional Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:repository.bilkent.edu.tr:...
Last time updated on 17/04/2018